Antiviral efficacy of fluoxetine in early symptomatic COVID-19: an open-label, randomised, controlled, adaptive platform trial (PLATCOV)Research in context

Summary: Background: The selective serotonin reuptake inhibitors (SSRIs) fluoxetine and fluvoxamine were repurposed for the treatment of early COVID-19 based on their antiviral activity in vitro, and observational and clinical trial evidence suggesting they prevented progression to severe disease....

Full description

Saved in:

Bibliographic Details
Main Authors:	Podjanee Jittamala, Simon Boyd, William H.K. Schilling, James A. Watson, Thundon Ngamprasertchai, Tanaya Siripoon, Viravarn Luvira, Elizabeth M. Batty, Phrutsamon Wongnak, Lisia M. Esper, Pedro J. Almeida, Cintia Cruz, Fernando R. Ascencao, Renato S. Aguiar, Najia K. Ghanchi, James J. Callery, Shivani Singh, Varaporn Kruabkontho, Thatsanun Ngernseng, Jaruwan Tubprasert, Wanassanan Madmanee, Kanokon Suwannasin, Amornrat Promsongsil, Borimas Hanboonkunupakarn, Kittiyod Poovorawan, Manus Potaporn, Attasit Srisubat, Bootsakorn Loharjun, Walter R.J. Taylor, Farah Qamar, Abdul Momin Kazi, M. Asim Beg, Danoy Chommanam, Sisouphanh Vidhamaly, Kesinee Chotivanich, Mallika Imwong, Sasithon Pukrittayakamee, Arjen M. Dondorp, Nicholas P.J. Day, Mauro M. Teixeira, Watcharapong Piyaphanee, Weerapong Phumratanaprapin, Nicholas J. White
Format:	Article
Language:	English
Published:	Elsevier 2025-02-01
Series:	EClinicalMedicine
Subjects:	SARS-CoV-2 Antivirals COVID-19 Viral clearance
Online Access:	http://www.sciencedirect.com/science/article/pii/S2589537024006151
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!

Antiviral efficacy of fluoxetine in early symptomatic COVID-19: an open-label, randomised, controlled, adaptive platform trial (PLATCOV)Research in context

Similar Items